• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1245604 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
5 Z+ A8 R3 o8 D3 o# V& u  q4 fNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 1 T& g; b; W# A& @. C2 e$ R
+ Author Affiliations
5 L. [4 }* f6 P! V
3 L: L, F+ Z6 Y" X, Z5 K. N/ L' ?1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan , j, c3 h. g8 B" u) f
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
4 C% y% u- C$ K/ \% N3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
0 |% N: @' I/ U- j* o# c3 d4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan + h+ b# W4 ]# h) d' r$ @0 d- H
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
. a! }" G  Y9 l$ R- l/ o( l* \6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
% }2 t& E# L! _! |7Kinki University School of Medicine, Osaka 589-8511, Japan ) i, B: j! |8 |" t' T
8Izumi Municipal Hospital, Osaka 594-0071, Japan
. ^( k1 G8 O3 n4 C2 d# T* L5 Q9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
8 I. R8 l0 r( OCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ! @) Z- T/ |' J# X) F  Y/ N
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
, }, {* _2 Y3 r+ a2 l
5 B* D8 b$ k" x' v7 I* a! C- R9 [
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
' R$ j4 x& r; Z; A6 d2 O
1 r9 E* W! c, g! w% I+ v' ^3 iAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato % T$ \- ?5 @8 ?% o/ H1 r! I

7 y, _0 q9 X% j1 [2 ^( \$ r& yAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
5 `! J( G0 E4 Q$ \
  ?3 J, _% B$ ], `' DPublished online on: Thursday, December 1, 2011
" @; Q- o" G1 I0 F( L) s7 ~- c( V: w+ E: @( t8 K2 u6 R
Doi: 10.3892/ol.2011.507
. ~' U. L% l. D  ^# B
( {1 i" |; O5 L5 rPages: 405-410
6 m1 Y; E1 S  D) V& Z/ ~# m# A" L; J3 d: }% o
Abstract:" G+ z' A2 |- k% D+ D) E- X$ ?
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
' k4 z6 Y' S8 ]. i2 f) u  Z
. P. ]; p( D5 \0 ~. N' Y& r, p) A* Q
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
( b+ D' K9 j$ z: _7 z% ^9 QF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
7 ^) U7 R+ }6 O6 a9 L+ Author Affiliations
; T8 N+ K2 y4 \5 Y1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
) m2 G) @0 s; ^1 c$ M3 }# t. `2Department of Thoracic Surgery, Kyoto University, Kyoto . }9 ~2 p$ y- n' l5 u$ R
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan 8 q1 f5 S2 A( @9 A. l
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 7 u/ g/ T- ~5 N
Received September 3, 2010. ' M, [2 E  a, L! r; B- r+ R) }
Revision received November 11, 2010.
* ^$ t% }  Y! A0 ^7 eAccepted November 17, 2010. - n0 X# E* c) y, U6 ?. w0 ]
Abstract+ g0 n: I! A8 Y3 ^; t/ L2 C, J# \
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. ( [# Z* o+ K8 S. K/ J9 |$ W
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
" G" Y7 w' J2 _! \0 `5 iResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
, D$ @2 X- F# U2 a. b5 l$ [8 dConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. 7 s, E0 K: I( T, ?+ J3 g; z0 \
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
( K& K/ C* }% I+ g% {$ a/ V今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?6 ^5 M4 C5 \) ?; S) y2 K
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy7 [) t) H" l, G( \/ G
http://clinicaltrials.gov/ct2/show/NCT01523587
# P0 S( E$ \+ |4 v. B, D; v! f0 a$ u
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
1 N% b1 ]( I1 n" ~. ~: O8 c  Whttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
+ u; F' o; ~1 I9 H6 ?
) W0 Q; Y% z; R* g- K1 B从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
; w, }& B/ I  d9 G至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 1 e' R& H( t  ?( [$ k
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
8 F3 ^6 n' o# c5 U2 d8 w) c( P至今为止,未出 ...
' P0 Z& j8 V4 l+ t
没有副作用是第一追求,效果显著是第二追求。
. h% w0 A) s6 B- ~  U4 N# Y不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表